Search Results 2001-2010 of 18787 for Relapse

  1. Highlights of Mayo Clinic research advancements in 2023

    "Currently there are six different CAR-T cell therapies approved for treatment of relapsed blood cancers. While the results are impressive, not everyone ...

  2. A Safety Study of SEA-TGT (SGN-TGT) in Patients With Advanced Cancer - Mayo Clinic

    participants should have had disease that has relapsed after or be refractory to intensive salvage chemotherapy, including autologous SCT. - PTCL-NOS ...

  3. Medulloblastoma Clinical Trials - Mayo Clinic Research

    ... Relapsed or Refractory Brain Tumors No Locations. This phase I trial studies the side effects and the best dose of wild-type reovirus (viral therapy) when ...

  4. Study Of Datopotamab Deruxtecan Plus Carboplatin Or Cisplatin Versus Gemcitabine Plus Carboplatin Or Cisplatin In Participants With Locally Advanced Or Metastatic Urothelial Carcinoma - Mayo Clinic

    NYHA Class III heart failure • Must have experienced radiographic progression or relapse during or after 1L of EV and pembrolizumab. Participant who ...

  5. Cancer and mental health: Mayo Clinic expert dispels myths

    "If I had one thing that I could tell all cancer patients, it would be that stress does not cause cancer. That is a common myth that causes a lot of unnecessary ...

  6. A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy - Mayo Clinic

    Patients who previously responded to CNIs (CsA or tacrolimus), rituximab, or alkylating agents with either a CR or PR and subsequently relapsed are eligible ...

  7. Bone marrow transplant - Mayo Clinic

    Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide-based haploidentical versus matched sibling donor reduced-intensity ...

  8. Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers - Mayo Clinic

    documented relapse or progression on or after the most recent line of therapy 4. no standard therapy options likely to convey clinical benefit 2. Adequate ...

  9. A Study to Evaluate TG4050 in Ovarian Carcinoma - Mayo Clinic

    Patients who have developed an asymptomatic relapse as defined by: Cohort A: CA-125 ≥ 2 times ULN on 2 occasions at least 1 week apart (GCIG criteria) or ...

  10. Peripheral T-cell lymphoma - Symptoms and causes - Mayo Clinic

    Treatment of relapsed or refractory peripheral T cell lymphoma. https://www.uptodate.com/contents/search. Accessed Dec. 30, 2025. Elsevier Point of Care ...